Ben Towne Center for Childhood Cancer Research

The Ben Towne Center’s mission is to translate scientific discoveries into innovative therapies that cure childhood cancer with minimal side effects and improve survivors’ quality of life.

Our Vision

We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.

Accelerating Progress Toward Cures

  • Goal: Cure Neuroblastoma

    Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.

  • We Need Your Help

    You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.

Participate in Research

Our researchers have started the first round of clinical trials exploring a potential cure.

Help us answer questions about childhood health and illness, and help other children in the future. Learn more.


Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.

Please visit Seattle Children’s careers page to learn about current openings.

For information about potential opportunities in the Ben Towne Center, email us.

Latest News

Faces of the Eastside – 03.17.2017 – 425 Magazine
Callie Lentz isn’t your typical sixth-grader. At just 12 years old, the Bellevue preteen already is the founder of her own company, Callie’s Coffee, where she’s made funding cancer research the heart of her mission. During the week, she’s a regular student at Chinook Middle School, but on the weekend, she jumps into philanthropy mode, attending fundraising events like Strong Against Cancer, an initiative inspired by the Seattle Children's Ben Towne Center for Childhood Cancer Research at Seattle Children’s Hospital.

Endocyte and Seattle Children’s Research Institute to collaborate – 03.10.2017 – Endocyte
Endocyte, Inc. announced their plan to collaborate with Seattle Children's Research Institute and Dr. Michael Jensen for the development of Endocyte's SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte's proprietary SMDC bi-specific adaptor molecules.

10 takeaways from the ASH Annual Meeting and Exposition01.06.17 – Healio/HemOnc Today The ASH Annual Meeting and Exposition featured the latest breakthroughs in treatment – including advances in immunotherapy and gene therapy – as well as advances in prevention and diagnosis of benign and malignant hematologic conditions. Dr. Rebecca Gardner of Seattle Children’s Hospital spoke with HemOnc Today about a study that evaluated an early intervention against cytokine release syndrome among patients with pre-B ALL who underwent anti-CD19 CAR T-cell therapy.